OncoMatch/Clinical Trials/NCT06496490
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
Is NCT06496490 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including TQB2102 for and TQB2102 for for non-small cell lung cancer.
Treatment: TQB2102 for · TQB2102 for — TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 2 study to evaluate the efficacy,and safety of TQB2102 for injection in locally advanced or metastatic non-small cell lung cancer with HER2 gene abnormality.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) gene abnormality
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatments
Previous standard treatments failed
Cannot have received: anticancer therapy or investigational drug
Any anticancer therapy or any other investigational drug treatment within 28 days or 5 half-lives prior to the first dosing of this study
Cannot have received: Chinese patent drugs with anti-tumor indications
Within 1 week prior to the first administration of this study, the Chinese patent drugs with anti-tumor indications clearly stated in the National MedicalProducts Administration approved drug instructions were treated
Cannot have received: local focal palliative radiotherapy
Local focal palliative radiotherapy was received within 2 weeks before the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify